Bristol Myers' new cancer partnership is promising, but doesn't change our stance on the stock yet

Bristol Myers Squibb (BMY) announced a licensing deal with BioNTech to jointly develop and commercialize BNT327, a dual-acting immuno-oncology cancer therapy, with a potential value of $11 billion to BioNTech, including $1.5 billion upfront and $2 billion in payments through 2028; however, BMY's stock gained less than 1% on the news, while BioNTech surged 19%, suggesting investor skepticism following a recent failed trial for schizophrenia treatment Cobenfy and concerns about upcoming patent expirations for key drugs like Revlimid and Eliquis, making BMY a "show-me story" as it seeks to bolster its pipeline and growth prospects.

Analysis

Bristol Myers Squibb (BMY) announced a significant licensing agreement with BioNTech to co-develop and co-commercialize BNT327, an experimental immuno-oncology (IO) cancer therapy, potentially valued at approximately $11 billion for BioNTech. This includes a $1.5 billion upfront payment from BMY and an additional $2 billion in milestone payments through 2028, with profits and losses to be shared equally. This move aims to bolster BMY's drug pipeline, particularly as it faces looming patent expirations for key revenue drivers like Revlimid, Eliquis, and its existing IO drug, Opdivo. The muted market reaction for BMY, whose stock rose less than 1% post-announcement compared to BioNTech's over 19% surge, underscores significant investor skepticism. This sentiment is largely attributed to BMY's recent challenges, including the failed trial of its schizophrenia treatment Cobenfy in April, which was viewed as critical for future revenue, and the stock's approximate 18% decline over the past three months. CEO Chris Boerner positioned the BioNTech deal as a new growth avenue, particularly for hard-to-treat solid tumors, leveraging BMY's experience with Opdivo. However, the company remains a "show-me story" for investors, who are seeking more tangible evidence of pipeline success. Adding to the complexity are potential US tariff hurdles on pharmaceuticals, though Boerner indicated active engagement with the administration to mitigate supply chain disruptions, highlighting that the majority of BMY's infrastructure and sales are US-based and referencing a recent $40 billion investment pledge in the U.S.

Key Decisions for Investors

• Investors should view the BioNTech deal as a strategically sound step to address pipeline concerns, but maintain a cautious stance given Bristol Myers Squibb's recent clinical trial setback with Cobenfy and the 'show-me' investor sentiment.
• Monitor upcoming clinical trial results for BNT327 and other pipeline candidates closely, as positive data will be crucial to rebuild investor confidence and demonstrate a clear path to offsetting revenue losses from patent expirations.
• Consider the current depressed valuation of BMY, but await further catalysts or a clearer resolution of uncertainties surrounding Cobenfy's long-term potential and the impact of patent cliffs before significantly increasing positions.
• Factor in the external risk of potential U.S. pharmaceutical tariffs, which could impact profitability, despite management's efforts to engage with policymakers.